Tag Archives: ibrance

June, 2018

December, 2017

April, 2017

December, 2016

April, 2016

February, 2016

  • 22 February

    FDA Expands Approval of Pfizer’s Ibrance in Metastatic Breast Cancer

    Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE® (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. Now IBRANCE also is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) …

June, 2015

April, 2015

February, 2015

  • 4 February

    Pfizer’s Breast Cancer Drug Receives Accelerated Approval from the FDA

    Federal health regulators have provided an early approval to Pfizer Inc.’s Breakthrough breast cancer drug palbociclib. The company announced that the US Food and Drug Administration (FDA) has granted accelerated approval of Ibrance (palbociclib) in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth …